Biokinetics and radiation dosimetry for [4-14C] cholesterol in humans

• Autorzy: Marcato L. A. , Hamada M. M. , de Mesquita C. H.
• Konferencja: Proceedings of the International Conference on Development and Applications of Nuclear Technologies NUTECH-2011, 11-14 September 2011, Kraków, Poland
• Języki publikacji: EN

Abstrakty

EN

This study proposes a biokinetic model for using in the assessment of the internal dose received by human subjects administered intravenously or orally with [4-14C]-cholesterol. The proposed model includes three systemic pools representing the short-term (T1/2 = 1 d), intermediate-term (T1/2 = 16 d) and long-term (T1/2 = 78 d) physiological exchanges and two excretion pathways: urine and feces. To validate the model, the predicted excretion and absorption of cholesterol was compared with that described in the literature. The radiometric doses were calculated in function of the phantom body mass (M) applying MIRD (medical internal radiation dose) protocol with ANACOMP software. The effective dose coefficients for oral administration were: 2.93×10–10 Sv.Bq–1 (73.3 kg); 3.84×10–10 Sv.Bq–1 (56.8 kg); 6.74 × 10–10 Sv.Bq–1 (33.2 kg) and 7.72 × 10–10 Sv.Bq–1 (19.8 kg). To determinate the dose for intermediate body mass M the polynomial interpolation can be used: Sv.Bq–1 (kg) = 6 × 10–15M3 – 8 × 10–13M2 + 2 × 10–11M + 6 × 10–10 (R2 ≅ 1). In the same way, for intravenous administration were: 3.72 × 10–10 Sv.Bq–1 (73.3 kg); 4.87 × 10–10 Sv.Bq–1 (56.8 kg); 8.49 × 10–10 Sv.Bq–1 (33.2 kg); 1.26 × 10–9 Sv.Bq–1 (19.8 kg). Similarly, for any M body mass: Sv.Bq–1 (kg) = –4 × 10–15M3 + 9 × 10–13M2 – 7 × 10–11M + 2 × 10–9 can be used.

Słowa kluczowe

EN

[4-14C]-cholesterol; internal dosimetry; dosimetric model; medical internal radiation dose (MIRD)

• Wydawca: Institute of Nuclear Chemistry and Technology
• Czasopismo: Nukleonika
• Rocznik: 2012
• Tom: Vol. 57, No. 4
• Strony: 607--613
• Opis fizyczny: Bibliogr. 21 poz., rys.

Twórcy

autor

Marcato L. A.

autor

Hamada M. M.

autor

de Mesquita C. H.

• Brazilian National Nuclear Energy Commission (CNEN/SP), Institute for Nuclear and Energy Research (IPEN), Radiation Technology Center (CTR), 2242 Prof. Lineu Prestes Ave., – Cidade Universitaria, 05508-000, Sao Paulo – SP, Brazil, Tel.: [phone],

Bibliografia

• 1. Borgstrom B (1969) Quantification of cholesterol absorption in man by fecal analysis after the feeding of a single isotope-labeled meal. J Lipid Res 10:331–337
• 2. Bosner MS, Ostlung RE, Osofisan O, Grosklos J, Fritschle C, Lange LG (1993) Assesment of percent cholesterol absorption in humans with stable isotopes. J Lipid Res 34:1047–1053
• 3. Connor WE, Lin DS (1974) The intestinal absorption of dietary cholesterol by hypercholesterolemic (type II) and normocholesterolemic humans. J Clin Invest 53:1062–1070
• 4. Dolphin GW, Eve IS (1966) Dosimetry of gastrointestinal tract. Health Phys 12:163–172
• 5. Eve IS (1966) A review of the physiology of the gastrointestinal tract in relation to radiation doses from radioactive materials. Health Phys 12:131–161
• 6. Grundy SM, Mok HYI (1977) Determination of cholesterol absorption in man by intestinal perfusion. J Lipid Res 18:263–271
• 7. Hellman L, Rosenfeld RS, Eidinoff ML et al. (1955) Isotopic studies of plasma cholesterol of endogenous and exogenous origin. J Clin Invest 34:48–60
• 8. ICRP (1975) Reference man: anatomical, physiological and metabolic characteristics. ICRP Publication 23. International Commission on Radiological Protection
• 9. ICRP (1979) Limits for intakes of radionuclides by workers. ICRP Publication 30. International Commission on Radiological Protection
• 10. ICRP (1991) Recommendations radiological protection. ICRP Publication 60. International Commission on Radiological Protection
• 11. ICRP (1995) Age-dependent doses to members of the public from intake of radionuclides. ICRP Publication 71. International Commission on Radiological Protection
• 12. Levitt MD, Hanson RF, Bond JH, Engel RR (1975) Failure to demonstrate degradation of [4-14C] cholesterol to volatile hydrocarbons in rats and in human fecal homogenates. Lipids 10:662–666
• 13. Makrigioros GM, Ito S, Baranowska-Kortiylewicz J (1990) Inhomogeneous deposition of radiopharmaceuticals at a cellular level: experimental evidence and dosimetric implications. J Nucl Med 31:1358–1363
• 14. Manger RP (2011) A generic biokinetic model for carbon-14. Radiat Prot Dosim 143:42–51
• 15. Marchese SR, Mesquita CH, Cunha IIL (1998) AnaComp program application to calculate 137Cs transfer rates in marine organisms and dose on the man. J Radioanal Nucl Chem 232:233–236
• 16. Samuel P, Crouse JR, Ahrens EHJ (1978) Evaluation of an isotope ratio method for measurement of cholesterol absorption in man. J Lipid Res 19:82–93
• 17. Stabin MG, Tagesson M, Thomas SR, Ljungberg M, Strand SE (1999) Radiation dosimetry in nuclear medicine. Appl Radiat Isot 50:73–87
• 18. Taylor DM (2000) Generic models for radionuclide dosimetry 11C-, 18F- or 75Se-labelled amino acids. Appl Radiat Isot 52:911–922
• 19. Taylor DM (2004) Biokinetic model for the behavior of carbon-14 from labeled compounds in the human body: can a single model be justified? Radiat Prot Dosim 108:187–202
• 20. USNRC (2010) Radiation protection and the NRC. NUREG/BR-0322. United States Nuclear Regulatory Commission, Washington
• 21. Zilversmit DB, Hughes LB (1974) Validation of a dual-isotope plasma ratio method for measurement of cholesterol absorption in rats. J Lipid Res 15:465–473